Napolitano, Daniele
 Distribuzione geografica
Continente #
NA - Nord America 229
EU - Europa 200
AS - Asia 24
AF - Africa 2
Totale 455
Nazione #
US - Stati Uniti d'America 228
SE - Svezia 67
IT - Italia 57
IE - Irlanda 23
FR - Francia 18
DE - Germania 10
KR - Corea 10
CN - Cina 8
SI - Slovenia 6
FI - Finlandia 4
PT - Portogallo 4
GB - Regno Unito 3
IN - India 2
UA - Ucraina 2
BG - Bulgaria 1
CA - Canada 1
CI - Costa d'Avorio 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JP - Giappone 1
MK - Macedonia 1
NG - Nigeria 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
SG - Singapore 1
Totale 455
Città #
Chandler 70
Ashburn 32
New York 27
Dublin 21
Rome 19
Marseille 12
Milan 10
Seoul 10
Beijing 8
Princeton 7
Boston 5
Bremen 4
Atlanta 3
Chelsea 3
Helsinki 3
Lisbon 3
San Diego 3
Washington 3
Cagliari 2
Fairfield 2
Florence 2
Houston 2
Oristano 2
Paris 2
Pune 2
Saint-Fons 2
San Mateo 2
Seattle 2
Abidjan 1
Arzachena 1
Augusta 1
Busto Arsizio 1
Ceriano Laghetto 1
Frankfurt am Main 1
Gdansk 1
Hirakata 1
Iesi 1
Lagos 1
Lappeenranta 1
Leawood 1
Los Angeles 1
Massa 1
Montreal 1
Monza 1
Munich 1
Ravenna 1
Sacramento 1
Singapore 1
Trieste 1
Wilmington 1
Zagreb 1
Totale 286
Nome #
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 56
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 53
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 49
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 44
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 43
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 42
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 39
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 29
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 28
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 21
Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre 17
Evaluation of factors associated with trust in telemedicine in patients with inflammatory bowel disease during COVID-19 pandemic: a multicenter cross-sectional survey 15
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 14
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 6
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 5
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 4
Knowledge of perianal Crohn's disease among nurses in an Italian tertiary centre 4
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 2
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 2
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 2
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 2
Totale 477
Categoria #
all - tutte 2.863
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.863


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213 0 0 0 0 0 0 0 0 0 0 1 2
2021/202258 1 0 0 2 1 0 0 3 0 18 16 17
2022/2023222 36 28 10 32 18 14 22 7 18 6 15 16
2023/2024194 6 40 16 19 11 35 21 7 17 21 1 0
Totale 477